Pharmaceuticals News and Research

RSS

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

Gamma Pharmaceuticals, Jugular form new joint venture company

Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

11 Mar 2010

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.

11 Mar 2010

WHO issues new guidelines for malaria treatment

The World Health Organization (WHO) is releasing new guidelines for the treatment of malaria, and the first ever guidance on procuring safe and efficacious anti-malarial medicines.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Comparative research lags far behind approval-driven evaluations

A new study has found that few drug evaluations compare treatments in ways that help doctors make better decisions, Reuters reports.

11 Mar 2010

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Cannabis Science, Inc., a pioneering pharmaceutical cannabis company, is pleased to announce that it has formalized its agreement with a privately owned, highly specialized international FDA regulatory compliance firm. The compliance firm will review and prepare technical data for Cannabis Science's FDA Pre-Investigative New Drug submission package for its Veterans PTSD Project.

11 Mar 2010

QLT announces results from Phase II clinical trials and device study for PPDS

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

11 Mar 2010

PBI and TDI announce strategic licensing and collaborative research and development agreement

Pressure BioSciences, Inc. and Target Discovery, Inc.,, today announced a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement. Under the terms of the Agreement, PBI has been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis.

11 Mar 2010

FDA sponsoring workshops to increase rare disease treatment options

The Wall Street Journal: FDA is putting on workshops for pharmaceutical manufacturers to increase the pool of applicants for approved "orphan drugs," that treat rare diseases. Currently, there are about 7,000 so-called orphan diseases in the U.S. that have few or no FDA-approved treatments.

11 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

Clinical trial shows eprotirome drug reduces blood cholesterol

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

11 Mar 2010

GSK to offer flexible drug pricing in middle-income countries

Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

Stason Pharmaceuticals to market Unilife's Unitract 1mL safety syringe in Japan, China and Taiwan

Unilife Corporation today announced that it has signed an exclusive five-year agreement with Stason Pharmaceuticals Inc, a U.S.-based pharmaceutical company, to market the Unitract™ 1mL safety syringe in Japan, China and Taiwan. Stason's Taiwan-based strategic alliance affiliate, Standard Chem. and Pharm. Co., LTD, will act as the primary distributor of the product within these designated territories.

10 Mar 2010

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

10 Mar 2010

OSI Pharmaceuticals deploys Veeva Systems' SaaS CRM application

Veeva Systems announced today that it will support OSI Pharmaceuticals, Inc. with its SaaS Customer Relationship Management (CRM) application, which OSI deployed to its sales team in February after a rapid implementation. OSI selected Veeva CRM® for its ease of use, relevant functionality, and speed.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010